𝛼SK or Search

ENTITY

Faron Pharmaceuticals Oy (FARN LN)

11

Analysis

Health Care • Finland

Faron Pharmaceuticals Oy operates as a drug discovery and development company in Finland. It has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy, and vascular damage. The company?s lead product candidate includes Traumakine, a recombinant human IFN beta-1a, which is Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS). It is also developing Clevegen, a pre-clinical immunotherapy candidate, designed to prevent tumor growth and metastasis which targets the tumor immune suppressor molecule; Farbetic, an AOC3 inhibitor, for use in the prevention of vascular deformations in various disease conditions, such as diabetes; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. The company was founded in 2003 and is based in Turku, Finland. Faron Pharmaceuticals Oy is a subsidiary of Faron Ventures Oy.

more

Refresh

Focused

bullish•Faron Pharmaceuticals Oy

•16 Apr 2026 17:20•Syndicated

Faron Pharmaceuticals: CRO selected for phase IIb study

Redeye comments on Faron announcing an agreement with Parexel to support the randomized phase IIb BEXERA trial of bexmarilimab in treatment-naïve...

Redeye

84 Views

Share

bullish•Faron Pharmaceuticals Oy

•10 Apr 2026 17:16•Syndicated

Faron Pharmaceuticals: Final outcome of EUR40m rights issue

Redeye comments on Faron’s announcement of the final outcome of its EUR40m rights issue, which delivered gross proceeds of approximately EUR40.1m...

Redeye

85 Views

Share

bullish•Faron Pharmaceuticals Oy

•10 Mar 2026 20:05•Syndicated

Faron Pharmaceuticals: Final terms of EUR40m rights issue

Redeye comments on Faron’s announcement of the final terms of its previously communicated rights issue. The company plans to raise approximately...

Redeye

84 Views

Share

bearish•Faron Pharmaceuticals Oy

•10 Feb 2026 17:51•Syndicated

Faron Pharmaceuticals: EUR40m rights issue announced

Redeye comments on Faron’s announcement of a planned fully pre-emptive rights issue of approximately EUR40m, aimed at funding the next phase of...

Redeye

83 Views

Share

bullish•Faron Pharmaceuticals Oy

•27 Jan 2026 18:00•Syndicated

Faron Pharmaceuticals: Pipeline expansion through investigator-led trials

Redeye comments on Faron’s announcements of the phase I/II investigator-initiated trials BEXAR and BLAZE, evaluating bexmarilimab in metastatic...

Redeye

88 Views

Share

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.69.1

x